Analyst Price Targets — CLGN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 2, 2024 11:47 am | Swayampakula Ramakanth | H.C. Wainwright | $11.00 | $4.34 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Collplant Holdings Inc. (CLGN) |
| August 5, 2024 7:52 am | Jason Kolbert | EF Hutton | $14.00 | $4.65 | StreetInsider | EF Hutton Starts Collplant Holdings Inc. (CLGN) at Buy |
Latest News for CLGN
Inhibrx Biosciences (NASDAQ: INBX - Get Free Report) and CollPlant Biotechnologies (NASDAQ: CLGN - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation. Risk and Volatility Inhibrx Biosciences has a
REHOVOT, Israel, March 26, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived rhCollagen for tissue regeneration and medical aesthetics, today announced its 2025 financial results and provided a corporate update. "Over the past year, we have made meaningful progress across all…
REHOVOT, Israel, March 24, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen) platform, today announced that on March 23, 2026, the Company received a written notice (the "Notice") from the Nasdaq Stock Market LLC indicating that the Company was…
REHOVOT, Israel, March 18, 2026 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary plant-derived recombinant human collagen (rhCollagen), today announced the launch of its redesigned corporate website at www.collplant.com . The new website provides expanded information regarding the Company's technology…
CollPlant Biotechnologies (NASDAQ: CLGN - Get Free Report) and CG Oncology (NASDAQ: CGON - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability. Earnings and Valuation This table compares CollPlant Biotechnologies
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CLGN.
U.S. House Trading
No House trades found for CLGN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.